Sipahi, Oguz ResatMermer, SinanDemirdal, TunaUlu, Ashhan CandevirFillatre, PierreOzcem, Selin BardakKaya, Safak2024-04-242024-04-2420180303-84671872-6968https://doi.org/10.1016/j.clineuro.2018.06.008https://hdl.handle.net/11468/15251Objectives: In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy. Patients and Methods: Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged > 18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016. Results: A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post therapy survival without any relapse or reinfection) decreased to 43%. Conclusion: We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multi drug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.eninfo:eu-repo/semantics/openAccessAcinetobacter BaumanniiMeningitisGlycylcyclineMultidrug Resistant BacteriaCarbapenem-ResistantArticle1723138WOS:0004429800000062-s2.0-850490963112996089310.1016/j.clineuro.2018.06.008Q2Q3